Skip to main navigation

Careers
Investors & Media
Contact

SCIENCE
PIPELINE
DISEASE FOCUS
HAE COMMUNITY
CLINICAL TRIALS
ABOUT US

Events

Investor Menu

IR Nav

Overview
News & Events
News Releases Events Publications
Financials
SEC Filings Quarterly Results
Stock
Stock Performance Analyst Coverage
Corporate Governance
Governance Documents Leadership Board of Directors Committee Composition
Resources
Investor FAQs Contact Us Email Alerts

Upcoming Events

May 13, 2024 9:30 AM EDT

The Citizens JMP Life Sciences Conference

Click for Webcast

Add to Google Calendar

May 16, 2024 11:00 AM EDT

BofA Securities Health Care conference 2024

Add to Google Calendar

Past Events

Feb 26, 2023 9:45 AM CST

AAAAI Annual Meeting 2023

Supporting Materials

Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial 1.1 MB

Dr. Marcus Maurer Audio Session (MP4) 6.3 MB

Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting

Dec 8, 2022 8:00 AM EST

RAPIDe-1 Phase 2 Top-line Data

Click for Webcast

Supporting Materials

Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks 193.1 KB

RAPIDe-1 Phase 2 Top-line Data Presentation 2.2 MB

Nov 10 - Nov 14, 2022

ACAAI Annual Scientific Meeting 2022

Supporting Materials

Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022

Development of PHVS719: an Oral Extended-Release Bradykinin B2 Receptor Antagonist to Prevent Hereditary Angioedema Attacks 818.4 KB

Pharmacokinetics of PHVS719, extended-release tablet formulation of PHA121, a first-in-class oral human bradykinin B2-receptor antagonist 937.4 KB

Oct 7, 2022 2:30 PM CEST

2022 HAEi Global Leadership Workshop

Supporting Materials

Development of two novel oral formulations of a first in class bradykinin B2 receptor antagonist for on demand and prophylactic treatment of hereditary angioedema 920.1 KB

Sep 16, 2022 10:45 AM CEST

2022 Bradykinin Symposium

Supporting Materials

Development of PHA121 for On-Demand and Prophylactic Treatment of HAE 926.6 KB

Jun 29, 2022 10:00 AM EDT

2022 Annual General Meeting of Shareholders

Supporting Materials

Annual Report and Auditor’s Report 2021 3.6 MB

Convening Notice and Agenda 1.1 MB

AGM Announcement 16.9 KB

Voting Proxy 251.6 KB

Jun 5 - Jun 8, 2022

Kinin2022 Conference

Supporting Materials

Pharvaris Kinin 2022 1.6 MB

Pharvaris Participates in the Kinin 2022 Conference

Jul 10 - Jul 16, 2021

European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021

Supporting Materials

Poster PHA022121 C006 EAACI2021 399.8 KB

Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021 338.2 KB

Jun 29, 2021 1:00 PM CEST

2021 Annual General Meeting of Shareholders

Supporting Materials

Annual Report and auditor's report 2020 1.9 MB

Convening Notice and Agenda (incl. explanatory notes) 185.3 KB

AGM Announcement 53.6 KB

Voting Proxy 154.9 KB

Jun 4, 2021 9:45 AM CEST

12th C1-Inhibitor Deficiency Angioedema Workshop

Supporting Materials

PHVS 2021 C1-INH Workshop Presentation 3.7 MB

Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE, at 12th C1 Inhibitor Deficiency and Angioedema Workshop

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Next page
Last page

Presentations

Corporate Presentation

FOLLOW US

©2024 Pharvaris N.V. © All Rights Reserved

Privacy Policy
Terms of Use